Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810221 | PMC |
| http://dx.doi.org/10.3201/eid2511.190912 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics and Laboratory Diagnoses of Pediatric Patients Hospitalized During an Outbreak of Mycoplasma pneumoniae.
APMIS
January 2025
Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
This study prospectively collected the clinical data, information on respiratory pathogens, and laboratory findings of children with Mycoplasma pneumoniae (M. pneumonia) infection who were hospitalized at the First Affiliated Hospital of Anhui Medical University during the M. pneumoniae outbreak in Hefei City, Anhui Province, China, between October 2023 and December 2023.
View Article and Find Full Text PDFIncreased antimicrobial resistance of isolates obtained from children in Beijing, China, in 2023.
Front Cell Infect Microbiol
January 2025
Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China.
Introduction: (), a common pathogen of community-acquired pneumonia in school-age children and adolescents, can cause epidemics worldwide. In late 2023, the incidence of infection among children reached a high level.
Methods: We investigated the antimicrobial susceptibility of 62 isolates obtained from children with pneumonia in Beijing between 2021 and 2023, and analyzed the correlation of antimicrobial susceptibility with molecular characteristics of isolates and clinical manifestations of patients.
Risk factors and prescription patterns analysis for macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
iScience
December 2024
Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
First-line macrolide therapy is encountering challenges due to the escalating incidence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP). This study aimed to illustrate prescription patterns among children diagnosed with either macrolide-sensitive Mycoplasma pneumoniae pneumonia (MSMPP) or MRMPP and to further analyze the risk factors associated with MRMPP. This research encompassed 825 children who were diagnosed with Mycoplasma pneumoniae pneumonia (MPP) at a tertiary hospital located in central China in 2023.
View Article and Find Full Text PDFTrends of Mycoplasma genitalium infections in Berlin, Germany, 2017-2023.
J Glob Antimicrob Resist
December 2024
Praxis Prenzlauer Berg, Berlin, Germany.
Objectives: The cell wall-less species Mycoplasma genitalium is a sexually transmitted pathogen with strong tendency to acquire resistance. Current knowledge about trends of resistance rates and differences between the risk population of men who have sex with men (MSM) and heterosexual patients as well as about circulating genotypes in both groups is limited.
Methods: Between August 2017 and December 2023, M.
The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae.
Curr Opin Infect Dis
December 2024
Department of Medicine, NYP/Weill Cornell Medical Center, New York, New York, USA.
Purpose Of Review: Define the utility of adjunctive macrolide therapy in patients with more severe forms of community-acquired pneumonia (CAP).
Recent Findings: Guidelines recommend adjunctive macrolide therapy as an option for patients with CAP, admitted to the hospital. A large data set collected both retrospectively and prospectively, including several recent randomized controlled trials (RCTs) have shown that adjunctive macrolide therapy can reduce mortality and improve outcomes in patients with severe CAP, more effectively than other alternative therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!